Proof-of-concept trial of ATI-50001 [A-201] in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2017
At a glance
- Drugs ATI 50001 (Primary)
- Indications Alopecia
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept
- Sponsors Aclaris Therapeutics
- 15 Mar 2017 Status changed from recruiting to completed, according to an Aclaris Therapeutics media release.
- 07 Dec 2016 According to Aclaris Therapeutics media release, company has initiated dosing of patients in this pharmacokinetic/pharmacodynamic (PK/PD) trial.
- 07 Dec 2016 Status changed from planning to recruiting, according to Aclaris Therapeutics media release.